We’re pleased to welcome back CEO Kelsey Ramsden from the psychedelics company Mind Cure Health Inc (CNSX: MCUR) (OTCMKTS: MCURF). Ramsden has interviewed with us before, sharing information about the company’s work on synthetic production of psychedelic molecule Ibogaine, and also the technical application known as iSTRYM. We’ll be focusing talks with Ramsden today on iSTRYM and how MINDCURE plans to roll it out.
Here’s some highlights from the interview.
What a proprietary protocol means for psychedelic-assisted psychotherapy
MINDCURE now has two proprietary Ketamine-enhanced protocols for psychedelic-assisted psychotherapy. Investors may not be certain what this means. Ramsden says that what makes the protocol special – proprietary – is that it’s not just the drug. It’s the set, setting, and actual theory behind the therapeutic approach. Or in short: it’s the giving of the drug and the caring for the person and the therapy that’s wrapped around it.
Ramsden says that Mitch Earleywine, a researcher out of the United States, helped MINDCURE develop therapeutic care packages for depression and pain management using Ketamine. Why is this important? They are the first protocols on the iSTRYM platform.
Ramsden says that if someone wants to use Ketamine in practices, these protocols are deployed through iSTRYM, so that therapists can have access to the protocols and care packages. This helps the industry grow and arms therapists with the best care practices, Ramsden says.
More protocols to be expected, says Ramsden
One of the features of iSTRYM is that people can upload their own protocols. She expects that certainly people will be doing it in research, even though some of it cannot be deployed in certain locations due to the illegality of psychedelics.
iSTRYM stands apart from other platforms in tools provided to therapists
Ramsden acknowledges there are similar platforms that help manage patients. But she says the key differentiation is in the in-session tools like AI-backed music, as well as post-session integration protocols.
The data collection and the tools help therapists understand how to get specific outcomes for specific patients, Ramsden says. For a therapist, it’s important to be able to provide this kind of hard data quickly to someone who is unsure they want to try psychedelic-assisted psychotherapy.
Launch of iSTRYM begins in August
The technology platform is set to launch this August, Ramsden says, with some key opinion leaders who will utilize the platform between then and January of 2022. These users will help point “the AI at the good data,” she says.
Beyond that, Ramsden says, there are a mix of people who are doing clinical programs out in the public, as well as research programs. She acknowledges that there’s currently a lot of uptake on the research side of things.
The third branch of interested users is people who want to open clinics themselves, and she says that there is a significant ramp-up of those who are identifying an opportunity to open their own psychedelic clinics.
iSTRYM not the only thing that MINDCURE is working on
Ramsden assures us that there will be clinical programs coming out of MINDCURE, particularly involving synthetic Ibogaine. As the first company to have the synthetic Ibogaine molecule, Ramsden does expect MINDCURE to be able to supply the market for indications such as opiate addiction, brain injury, and more.